Explore
Validate
Learn
Western blot
Immunocytochemistry
ImmunohistochemistryAntibody data
- Antibody Data
- Antigen structure
- References [7]
- Comments [0]
- Validations
- Immunocytochemistry [2]
Submit
Validation data
Reference
Comment
Report error
- Product number
- ALX-804-457-C125 - Provider product page
- Provider
- Enzo Life Sciences
- Proper citation
- Enzo Life Sciences Cat#ALX-804-457-C125, RRID:AB_2052416
- Product name
- Proteinase inhibitor 9 (human) monoclonal antibody (PI9-17)
- Antibody type
- Monoclonal
- Antigen
- Recombinant full length protein
- Reactivity
- Human
- Host
- Mouse
- Isotype
- IgG
- Antibody clone number
- PI9-17
- Vial size
- 125 μg
- Storage
- -20°C
Submitted references Ectopic expression of the serine protease inhibitor PI9 modulates death receptor-mediated apoptosis.
Expression of the apoptosis inhibitor protease inhibitor 9 predicts clinical outcome in vaccinated patients with stage III and IV melanoma.
High numbers of tumour-infiltrating activated cytotoxic T lymphocytes, and frequent loss of HLA class I and II expression, are features of aggressive B cell lymphomas of the brain and testis.
Hyperexpression of the granzyme B inhibitor PI-9 in human renal allografts: a potential mechanism for stable renal function in patients with subclinical rejection.
Modulators of inflammation use nuclear factor-kappa B and activator protein-1 sites to induce the caspase-1 and granzyme B inhibitor, proteinase inhibitor 9.
Expression of the granzyme B inhibitor, protease inhibitor 9, by tumor cells in patients with non-Hodgkin and Hodgkin lymphoma: a novel protective mechanism for tumor cells to circumvent the immune system?
The granzyme B inhibitor, protease inhibitor 9, is mainly expressed by dendritic cells and at immune-privileged sites.
Kummer JA, Micheau O, Schneider P, Bovenschen N, Broekhuizen R, Quadir R, Strik MC, Hack CE, Tschopp J
Cell death and differentiation 2007 Aug;14(8):1486-96
Cell death and differentiation 2007 Aug;14(8):1486-96
Expression of the apoptosis inhibitor protease inhibitor 9 predicts clinical outcome in vaccinated patients with stage III and IV melanoma.
van Houdt IS, Oudejans JJ, van den Eertwegh AJ, Baars A, Vos W, Bladergroen BA, Rimoldi D, Muris JJ, Hooijberg E, Gundy CM, Meijer CJ, Kummer JA
Clinical cancer research : an official journal of the American Association for Cancer Research 2005 Sep 1;11(17):6400-7
Clinical cancer research : an official journal of the American Association for Cancer Research 2005 Sep 1;11(17):6400-7
High numbers of tumour-infiltrating activated cytotoxic T lymphocytes, and frequent loss of HLA class I and II expression, are features of aggressive B cell lymphomas of the brain and testis.
Riemersma SA, Oudejans JJ, Vonk MJ, Dreef EJ, Prins FA, Jansen PM, Vermeer MH, Blok P, Kibbelaar RE, Muris JJ, Schuuring EM, Kluin PM
The Journal of pathology 2005 Jul;206(3):328-36
The Journal of pathology 2005 Jul;206(3):328-36
Hyperexpression of the granzyme B inhibitor PI-9 in human renal allografts: a potential mechanism for stable renal function in patients with subclinical rejection.
Rowshani AT, Florquin S, Bemelman F, Kummer JA, Hack CE, Ten Berge IJ
Kidney international 2004 Oct;66(4):1417-22
Kidney international 2004 Oct;66(4):1417-22
Modulators of inflammation use nuclear factor-kappa B and activator protein-1 sites to induce the caspase-1 and granzyme B inhibitor, proteinase inhibitor 9.
Kannan-Thulasiraman P, Shapiro DJ
The Journal of biological chemistry 2002 Oct 25;277(43):41230-9
The Journal of biological chemistry 2002 Oct 25;277(43):41230-9
Expression of the granzyme B inhibitor, protease inhibitor 9, by tumor cells in patients with non-Hodgkin and Hodgkin lymphoma: a novel protective mechanism for tumor cells to circumvent the immune system?
Bladergroen BA, Meijer CJ, ten Berge RL, Hack CE, Muris JJ, Dukers DF, Chott A, Kazama Y, Oudejans JJ, van Berkum O, Kummer JA
Blood 2002 Jan 1;99(1):232-7
Blood 2002 Jan 1;99(1):232-7
The granzyme B inhibitor, protease inhibitor 9, is mainly expressed by dendritic cells and at immune-privileged sites.
Bladergroen BA, Strik MC, Bovenschen N, van Berkum O, Scheffer GL, Meijer CJ, Hack CE, Kummer JA
Journal of immunology (Baltimore, Md. : 1950) 2001 Mar 1;166(5):3218-25
Journal of immunology (Baltimore, Md. : 1950) 2001 Mar 1;166(5):3218-25
No comments: Submit comment
Supportive validation
- Submitted by
- Enzo Life Sciences (provider)
- Main image
- Experimental details
- Tissue sections of T-ALCL a) stained with MAb to PI9 (Prod. No. ALX-804-457) and b) double-stained with MAb to PI9 (red)Ê(Prod. No. ALX-804-457) and granzyme B (brown). In panelÊb the arrows point to tumor-infiltrating CTLs positive for granzyme B and the arrowhead denotes an example of a PI9+ neoplastic cell.
- Submitted by
- Enzo Life Sciences (provider)
- Main image
- Experimental details
- The following tumors were stained for PI9: a) B-CLL and b) classical Hodgkin disease, nodular sclerosing subtype.
